- Home
- ASIC vs NVAX Comparison
ASIC vs NVAX Comparison
Compare ASIC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIC
- NVAX
- Stock Information
- Founded
- ASIC 2018
- NVAX 1987
- Country
- ASIC United States
- NVAX United States
- Employees
- ASIC N/A
- NVAX N/A
- Industry
- ASIC Property-Casualty Insurers
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASIC Finance
- NVAX Health Care
- Exchange
- ASIC Nasdaq
- NVAX Nasdaq
- Market Cap
- ASIC 1.2B
- NVAX 1.3B
- IPO Year
- ASIC 2025
- NVAX 1995
- Fundamental
- Price
- ASIC $23.51
- NVAX $7.02
- Analyst Decision
- ASIC
- NVAX Buy
- Analyst Count
- ASIC 0
- NVAX 5
- Target Price
- ASIC N/A
- NVAX $19.00
- AVG Volume (30 Days)
- ASIC 1.1M
- NVAX 11.4M
- Earning Date
- ASIC 01-01-0001
- NVAX 08-07-2025
- Dividend Yield
- ASIC N/A
- NVAX N/A
- EPS Growth
- ASIC N/A
- NVAX N/A
- EPS
- ASIC 0.12
- NVAX 2.97
- Revenue
- ASIC $350,888,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- ASIC N/A
- NVAX $56.85
- Revenue Next Year
- ASIC N/A
- NVAX N/A
- P/E Ratio
- ASIC $200.01
- NVAX $2.33
- Revenue Growth
- ASIC N/A
- NVAX 25.92
- 52 Week Low
- ASIC $22.00
- NVAX $5.01
- 52 Week High
- ASIC $25.30
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- ASIC N/A
- NVAX 50.06
- Support Level
- ASIC N/A
- NVAX $6.87
- Resistance Level
- ASIC N/A
- NVAX $7.80
- Average True Range (ATR)
- ASIC 0.00
- NVAX 0.40
- MACD
- ASIC 0.00
- NVAX -0.04
- Stochastic Oscillator
- ASIC 0.00
- NVAX 19.27
About ASIC Ategrity Specialty Insurance Company Holdings Common Stock
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.